CN110831626B - 单价抗备解素抗体及抗体片段 - Google Patents

单价抗备解素抗体及抗体片段 Download PDF

Info

Publication number
CN110831626B
CN110831626B CN201880008892.6A CN201880008892A CN110831626B CN 110831626 B CN110831626 B CN 110831626B CN 201880008892 A CN201880008892 A CN 201880008892A CN 110831626 B CN110831626 B CN 110831626B
Authority
CN
China
Prior art keywords
antibody
seq
properdin
monovalent
antibody fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880008892.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN110831626A (zh
Inventor
道格拉斯.L.谢里登
保罗.P.腾博尼
塔妮莎·安-塔纳拉·麦克
沃尔特·C·韦格特里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Priority to CN202410325026.7A priority Critical patent/CN118184777A/zh
Publication of CN110831626A publication Critical patent/CN110831626A/zh
Application granted granted Critical
Publication of CN110831626B publication Critical patent/CN110831626B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201880008892.6A 2017-01-30 2018-01-30 单价抗备解素抗体及抗体片段 Active CN110831626B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410325026.7A CN118184777A (zh) 2017-01-30 2018-01-30 单价抗备解素抗体及抗体片段

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762452187P 2017-01-30 2017-01-30
US62/452,187 2017-01-30
PCT/US2018/015985 WO2018140956A1 (en) 2017-01-30 2018-01-30 Monovalent anti-properdin antibodies and antibody fragments

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410325026.7A Division CN118184777A (zh) 2017-01-30 2018-01-30 单价抗备解素抗体及抗体片段

Publications (2)

Publication Number Publication Date
CN110831626A CN110831626A (zh) 2020-02-21
CN110831626B true CN110831626B (zh) 2024-04-19

Family

ID=62978808

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880008892.6A Active CN110831626B (zh) 2017-01-30 2018-01-30 单价抗备解素抗体及抗体片段
CN202410325026.7A Pending CN118184777A (zh) 2017-01-30 2018-01-30 单价抗备解素抗体及抗体片段

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410325026.7A Pending CN118184777A (zh) 2017-01-30 2018-01-30 单价抗备解素抗体及抗体片段

Country Status (12)

Country Link
US (3) US11198725B2 (https=)
EP (1) EP3573661A4 (https=)
JP (3) JP7101684B2 (https=)
KR (2) KR102613874B1 (https=)
CN (2) CN110831626B (https=)
AU (2) AU2018212012B2 (https=)
BR (1) BR112019014652A2 (https=)
CA (1) CA3049806A1 (https=)
CO (1) CO2019007686A2 (https=)
IL (2) IL267898B2 (https=)
MX (3) MX2019008827A (https=)
WO (1) WO2018140956A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019008827A (es) * 2017-01-30 2019-09-26 Alexion Pharma Inc Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo.
KR102806328B1 (ko) * 2017-07-11 2025-05-14 알렉시온 파마슈티칼스, 인코포레이티드 보체 성분 c5 또는 혈청 알부민에 결합하는 폴리펩티드 및 그의 융합 단백질
JP7222075B2 (ja) * 2018-09-13 2023-02-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｃ３糸球体症のモデルとしての補体因子ｈ遺伝子ノックアウトラット
US12570732B2 (en) 2020-01-08 2026-03-10 Zydus Lifesciences Limited Anti-properdin antibodies and preparation thereof
CN116437913A (zh) 2020-09-23 2023-07-14 艾其林医药公司 用于治疗补体介导的病症的药物化合物
CN118436786A (zh) * 2020-10-30 2024-08-06 广州市妇女儿童医疗中心 诊治胆道闭锁的方法
WO2023023227A1 (en) 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Methods for treating sickle cell disease or beta thalassemia using complement alternative pathway inhibitors
US11981727B2 (en) 2021-08-31 2024-05-14 Novelmed Therapeutics, Inc Monospecific and bispecific antibodies and antigen binding fragments thereof
WO2024108529A1 (en) * 2022-11-25 2024-05-30 Linno Pharmaceuticals Inc. Properdin binding protein and use thereof
CA3264087A1 (en) * 2022-08-05 2024-02-08 Alexion Pharmaceuticals, Inc. Pharmaceutical compositions based on fusion proteins and their methods of use
CN120018862A (zh) * 2022-08-31 2025-05-16 阿雷克森制药公司 用于治疗镰状细胞病的融合多肽的剂量和施用
KR20250112858A (ko) 2022-11-25 2025-07-24 리노 파마슈티컬스 아이엔씨. 프로퍼딘 결합 단백질 및 이의 용도
CN120399074B (zh) * 2023-06-02 2025-12-30 安徽金百奥生物科技有限公司 一种与人dr3胞外域高亲和力的纳米抗体

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103796664A (zh) * 2011-07-01 2014-05-14 宾夕法尼亚大学董事会 抗备解素抗体和其应用
CN104114576A (zh) * 2011-12-21 2014-10-22 诺华股份有限公司 用于抗体靶定p因子的组合物和方法
CN104114187A (zh) * 2011-12-28 2014-10-22 诺沃姆德治疗公司 去糖基化的人类抗体、其融合蛋白质及用途
CN110003335A (zh) * 2019-04-12 2019-07-12 深圳普瑞金生物药业有限公司 Cd47单域抗体的vhh链、cd47单域抗体、核苷酸序列及试剂盒

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
BRPI0606934A2 (pt) 2005-01-25 2017-07-11 Cell Therapeutics Inc Conjugado de proteína biologicamente ativa, composição, molécula de dna quimérica, vetor, célula, e, métodos para preparar conjugado de proteína biologicamente ativa, e para determinar se um dado conjugado de proteína exibe uma meia-vida de plasma modificada comparada com a meia-vida intrínseca do polipeptídeo biologicamente ativo não conjungado
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
SG10201804008UA (en) * 2005-11-04 2018-06-28 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
DK2262831T3 (en) * 2008-03-03 2015-04-27 Novelmed Therapeutics Inc ANTI-Properdin ANTIBODIES
CA2766565A1 (en) 2009-06-23 2010-12-29 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
US20110172398A1 (en) 2009-10-02 2011-07-14 Boehringer Ingelheim International Gmbh Bispecific binding molecules for anti-angiogenesis therapy
CA2811221C (en) * 2010-03-10 2018-01-09 Novelmed Therapeutics, Inc. Humanized and chimeric anti-properdin antibodies
PT2621515T (pt) 2010-09-28 2017-07-12 Aegerion Pharmaceuticals Inc Polipéptido quimérico de leptina de foca-ser humano com solubilidade aumentada
AU2011328246B2 (en) 2010-11-08 2016-06-30 Ablynx N.V. CXCR2 binding polypeptides
JP6006309B2 (ja) 2011-07-08 2016-10-12 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
CA2887050A1 (en) 2012-10-04 2014-04-10 Novelmed Therapeutics, Inc. Alternative pathway specific antibodies for treating hemolytic diseases
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
MX2019008827A (es) * 2017-01-30 2019-09-26 Alexion Pharma Inc Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103796664A (zh) * 2011-07-01 2014-05-14 宾夕法尼亚大学董事会 抗备解素抗体和其应用
CN104114576A (zh) * 2011-12-21 2014-10-22 诺华股份有限公司 用于抗体靶定p因子的组合物和方法
CN104114187A (zh) * 2011-12-28 2014-10-22 诺沃姆德治疗公司 去糖基化的人类抗体、其融合蛋白质及用途
CN110003335A (zh) * 2019-04-12 2019-07-12 深圳普瑞金生物药业有限公司 Cd47单域抗体的vhh链、cd47单域抗体、核苷酸序列及试剂盒

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Properties, production, and applications of camelid single-domain antibody fragments;M.M.Harmsen等;Applied Microbiology and Biotechnology;第77卷(第77期);13-22 *

Also Published As

Publication number Publication date
AU2025200709A1 (en) 2025-02-20
RU2019124873A (ru) 2021-03-01
MX2019008827A (es) 2019-09-26
RU2019124873A3 (https=) 2021-03-01
JP2022153405A (ja) 2022-10-12
US20190352381A1 (en) 2019-11-21
MX2023007840A (es) 2023-07-07
MX2023004333A (es) 2023-05-04
JP7101684B2 (ja) 2022-07-15
EP3573661A1 (en) 2019-12-04
AU2018212012A1 (en) 2019-07-25
US11198725B2 (en) 2021-12-14
IL267898A (en) 2019-09-26
JP2024116321A (ja) 2024-08-27
US12497445B2 (en) 2025-12-16
KR20190111946A (ko) 2019-10-02
EP3573661A4 (en) 2020-08-12
BR112019014652A2 (pt) 2020-08-18
US20220162292A1 (en) 2022-05-26
CA3049806A1 (en) 2018-08-02
IL309890A (en) 2024-03-01
CO2019007686A2 (es) 2019-07-31
KR20230173731A (ko) 2023-12-27
US20260070963A1 (en) 2026-03-12
WO2018140956A1 (en) 2018-08-02
IL267898B1 (en) 2024-02-01
AU2018212012B2 (en) 2025-02-13
JP2020507561A (ja) 2020-03-12
KR102613874B1 (ko) 2023-12-15
CN118184777A (zh) 2024-06-14
IL267898B2 (en) 2024-06-01
CN110831626A (zh) 2020-02-21

Similar Documents

Publication Publication Date Title
CN110831626B (zh) 单价抗备解素抗体及抗体片段
US11286312B2 (en) Multispecific antibodies
US20250163138A1 (en) Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
CN102257009A (zh) 具有针对dc-sign的结合特异性的配体
RU2790103C2 (ru) Моновалентные антитела к пропердину и фрагменты антител
HK40112563A (zh) 单价抗备解素抗体及抗体片段
HK40024594A (en) Monovalent anti-properdin antibodies and antibody fragments
HK40024594B (zh) 单价抗备解素抗体及抗体片段
WO2023034842A2 (en) Monospecific and bispecific antibodies and antigen binding fragments thereof
CN117986364A (zh) 特异性结合cd39的纳米抗体及其用途
HK40027205A (en) Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40024594

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: Massachusetts, USA

Patentee after: Alexion pharmaceutical Co.

Country or region after: U.S.A.

Address before: Connecticut, USA

Patentee before: Alexion pharmaceutical Co.

Country or region before: U.S.A.

TG01 Patent term adjustment

Free format text: NEW EXPIRY DATE: 20380924

TG01 Patent term adjustment